CYP1A2 and attention deficit-hyperactivity disorder: Viloxazine also has a pharmacokinetic profile compatible with once-daily dosing, although clinically relevant drug interactions may occur through CYP1A2 inhibition.<h4>Conclusion</h4>Viloxazine expands the range of non-stimulant treatment options for ADHD and represents a successful example of drug repurposing in neuropsychiatry.